{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"2.53","value":"0.99"},{"groupId":"OG001","lowerLimit":"0.95","upperLimit":"2.43","value":"0.99"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"description":"Progression free survival is defined as time from first dose to disease progression, as defined by IWG criteria, or death due to any cause, whichever occurs earlier. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants received GSK3326595 400 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG000","title":"Part 1: GSK3326595 400 mg"},{"description":"Participants received GSK3326595 300 mg, tablets, orally, once daily until progression, unacceptable toxicity, or withdrawal of consent during Part 1 of the study.","id":"OG001","title":"Part 1: GSK3326595 300 mg"}],"paramType":"MEDIAN","populationDescription":"All Treated Population.","reportingStatus":"POSTED","timeFrame":"Up to 30.8 months","title":"Part 1: Progression Free Survival","type":"SECONDARY","unitOfMeasure":"Months"}